DS1040b/Aspirin Drug/Drug Interaction Study

NCT02071004 ↗

Phase 1 Completed 18 enrolled Daiichi Sankyo

Non-randomizedSingle-groupOpen-labelBasic science

Summary

This is a phase 1, open label, single dose study, after 5 days of aspirin treatment, in healthy male and female subjects. It is hypothesized that co-administering DS-1040b with aspirin at steady state will be safe and well tolerated by healthy male and female subjects.

Timeline

Start: 2014-01
Primary completion: 2014-02
Completion: 2014-02

Publications

Limsakun T, Dishy V, Mendell J, Pizzagalli F, Pav J, Kochan J, Vandell AG, Rambaran C, Kobayashi F, Orihashi Y, Warren V, McPhillips P, Zhou J. Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. J Clin Pharmacol. 2020 Jun;60(6):691-701. doi: 10.1002/jcph.1568. Epub 2020 Feb 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DS-1040b	Small molecule	6 mg	Intravenous
Background	Aspirin	Small molecule	75 mg	—

DS1040b/Aspirin Drug/Drug Interaction Study

Summary

Timeline

Publications

Drugs

Indications